- Home
- CISS vs PMCB Comparison
CISS vs PMCB Comparison
Compare CISS & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CISS | PMCB |
|---|---|---|
| Founded | 2022 | 1996 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 5.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CISS | PMCB |
|---|---|---|
| Price | $0.25 | $1.02 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 875.3K | ★ 9.9M |
| Earning Date | 11-18-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $33,613,149.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $0.65 | $162.06 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.63 |
| 52 Week High | $11.52 | $1.90 |
Technical Indicators
Market Signals| Indicator | CISS | PMCB |
|---|---|---|
| Relative Strength Index (RSI) | 15.99 | 56.81 |
| Support Level | $1.76 | $0.71 |
| Resistance Level | $1.94 | $1.51 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 0.97 | 44.32 |
Price Performance
Historical ComparisonAbout CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.